Ensuring that all patients have equal access to participate in clinical trials across all geographies has become essential throughout the industry. Patient recruitment and retention remain one of the most challenging hurdles in clinical development, particularly for rare diseases. Implementing a patient-focused clinical trial design and fostering a collaborative approach between the Sponsor, CRO, sites, and advocacy groups can help lead to successful clinical trials.
Given the daily obstacles faced by patients with rare diseases, including late onset Pompe disease, it is critical to minimize patient burden while recruiting a committed group of patients. Once recruited into a clinical study, it becomes paramount to provide ongoing support by focusing on the needs and concerns of the patient. This enhances patient retention, facilitating the collection of vital data for primary endpoints, which ultimately leads to faster therapies to market to give the patient community a treatment option.
In this webinar, Medpace, a global full-service CRO, discusses the importance of equity in patient-friendly rare disease trials. Additionally, experts discuss strategies in creating a positive clinical trial experience through a collaborative approach between sites, the Sponsor, and the CRO.
Watch the Rare Disease Day 2024 webinar to join the discussion with clinical trial experts on a collaborative approach to patient-friendly trials in rare disease.
Innovative Patient Enrollment and Retention Approaches for Rare Disease Clinical Trials
Rare disease clinical trials present a unique set of challenges in terms of clinical trial design, regulatory strategy, site selection, patient enrollment, and project management. These trials demand a highly experienced, full-service CRO with innovative strategies to identify and engage sites and scarce patient populations, with expertise in site and project management to achieve study aims.
Drive patient recruitment and site selection for difficult-to-recruit studies with guidance from our experienced team of cross-functional, rare disease experts, innovative study approaches, and strong site relationships.